Muneki Nagao

This inventor holds 5 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Kyorin Pharmaceutical Co., Ltd.. Active years: 2013-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Muneki Nagao. Retrieved from https://idiyas.com/inventor/muneki-nagao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 2)

% Patents Active = 20.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

5 out of 185

Kyorin Pharmaceutical Co., Ltd.

patents

Years Active: 2013-2019

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE47785 - 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal (2019-12-30),

2. 9328089 - 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-YL}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal (2016-05-03),

3. 9108915 - Method for producing 3,4-disubstituted pyrrolidine derivative (2015-08-18),

4. 9090587 - 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluorodethyl)-acid crystal (2015-07-28),

5. 8501965 - Method for producing 3-substituted-4-fluoropyrrolidine derivative (2013-08-06),

Title: Muneki Nagao - Innovator in Pharmaceutical Research

Introduction

Muneki Nagao is an inventor based in Shiraoka-shi, Japan. He is known for his contributions to pharmaceutical research, particularly in the area of MRGPRX2 antagonists. Although he currently holds no granted patents, his work is significant in the field of medicinal chemistry.

Latest Patent Applications

Muneki Nagao's latest patent applications include innovative compounds aimed at treating MRGPRX2-mediated diseases or disorders. The applications detail pharmaceutical compositions that comprise these compounds, which are represented by a specific structural formula. These compositions are designed to provide therapeutic benefits for conditions associated with MRGPRX2.

Conclusion

Muneki Nagao's research and patent applications reflect his commitment to advancing pharmaceutical science. His work on MRGPRX2 antagonists holds promise for future medical treatments.

Profile summary based on public USPTO records.